期刊
MEDICINA-LITHUANIA
卷 59, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/medicina59030542
关键词
upadacitinib; atopic dermatitis; ulcerative colitis; patient selection; Janus kinase
JAK inhibitors have shown efficacy in treating immune-related diseases such as ulcerative colitis and atopic dermatitis. This case report demonstrates the successful management of a patient with overlapping conditions of ulcerative colitis and atopic dermatitis using upadacitinib, resulting in complete and persistent clinical remission. These findings suggest that upadacitinib may be an optimal treatment strategy for individuals with coexisting Th1 and Th2-mediated conditions.
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis. These drugs target the Janus Kinase intracellular cascade, rendering them suitable for treating both Th1 and Th2 immune-mediated responses. Materials and Methods: We report the case of a 36-year-old male patient presenting an overlap of ulcerative colitis, a Th1-related disease, and atopic dermatitis, a Th2-mediated condition. Treatment with upadacitinib was initiated, and laboratory and instrumental follow-ups were carried out for 8 months. Results: The complete and persistent clinical remission of both conditions was observed at a low dose of 15 mg of upadacitinib, even though ulcerative colitis guidelines usually recommend a dosage of 45 mg. No serious adverse responses to therapy were reported. Conclusions: Upadacitinib may be the most suitable management strategy in subjects with coexisting severe conditions mediated by Th1 inflammation, such as ulcerative colitis, and by Th2 cytokines, such as atopic dermatitis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据